Precio WuXi XDC Cayman Inc (02268.HK)

WuXi XDC Cayman, Inc. is an investment holding company, which engages in research, discovery, development, and manufacturing of the drug substances and drug products of antibody drug conjugates and other bio conjugates. The company is headquartered in Wuxi, Jiangsu and currently employs 2,270 full-time employees. The company went IPO on 2023-11-17. The firm's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The firm provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The firm principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.